

Emyria receives \$2,527,316 R&D tax incentive refund

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) focused on delivering and developing new treatments for mental health and select neurological conditions, announces it has received a Research and Development (R&D) Tax Incentive refund of \$2,527,316 for research activity performed during the financial year 2022/2023.

Dr. Michael Winlo, CEO and MD, said: *“This substantial cash refund reflects Emyria's deep investment into mental health research and development over the past financial year and follows our key specialist psychiatrist obtaining Authorised Prescriber status last week.*

The period was marked by significant milestones in our quest to develop and deliver innovative mental health treatments for the large number of patients who are not able to find relief through conventional care.

This cash refund helps strengthen the expansion of our clinical services and our robust drug development pipeline and we look forward to providing further updates on these initiatives in 2024.”

The R&D Tax Incentive is an Australian Government program to support Australian companies undertake R&D activities in Australia. Eligible companies can receive cash rebates of up to 43.5% of eligible expenditure on R&D activities.

FOR FURTHER INFORMATION


Managing Director
Michael Winlo
+61 (0) 8 6559 2800
mwinlo@emyria.com

Media Contact
Haley Chartres
+61 (0) 423 139 163
haley@hck.digital

Corporate Advisor
Sufian Ahmed
+61 (0) 412 316 162
info@62capital.com.au

EMYRIA'S INTERACTIVE INVESTOR HUB

[Investorhub.emyria.com](https://investorhub.emyria.com) Interact with Emyria's announcements and updates by asking questions and comments, which our team can respond to where possible.



This release has been approved by the Managing Director of Emyria.

Emyria Limited is focused on developing and delivering new treatments for mental health and select neurological conditions through a unique business model combining clinical services and drug development:

generates

Emyria's Healthcare: Delivers evidence-based treatments for patients not finding relief from conventional care while also helping evaluate emerging new therapies like MDMA-assisted therapy for PTSD ¹

informs

Emyria Data: Robust and ethically-sourced Real-World Data gathered with patients and integrated into an advanced data platform powered by Palantir. Emyria data is used to improve Emyria's distinct therapy and drug development programs.

Emyria's Pipeline: One of the world's largest libraries of unique MDMA-like compounds developed in partnership with the University of Western Australia seeking new psychedelic-assisted therapies and treatments for neurological diseases and unique, highly potent dose forms of Ultra-Pure cannabinoids seeking registration for a range of mental health and neuroscience indications.

References:

1. The availability of these products is subject to the safety and efficacy of the products being tested through clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the products' ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD. There are currently no approved products containing MDMA that the TGA has evaluated for quality, safety and efficacy. Consumers should be aware that MDMA may cause side effects, as set out in the "Risks associated with the use of MDMA" in this announcement.

CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.